In vitro testing of the immune response

Aj, Cochran

doi:10.1007/978-94-010-9418-4_10

Cited by 10 publications

(7 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune reactivity against tumor-associated antigens has been demonstrated in a variety of neoplasms, such as Burkitt's lymphoma, malignant melanoma, neuroblastoma, and sarcoma [6,9,13]. For squamous cell carcinoma of the uterine cervix, several authors have reported the presence of antibodies against tumor-associated cell-surface antigens in serum of patients [4,5,31].…”

Section: Introductionmentioning

confidence: 99%

“…A number of assays for tumor-specific antibodies have been described [4,13,15,17,20,31]; the immunofluorescence technique appears to be the most sensitive [6]. Two different immunofluorescence techniques have been applied; when alcohol-acetone-fixed cells are used as target cells antibodies directed to cytoplasmic antigens are detected, whereas when living cells in suspension are used antibodies directed to cell-membrane antigens are detected.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor-specific antibodies in sera from patients with squamous cell carcinoma of the uterine cervix

Linde¹,

Streefkerk²,

Velde³

et al. 1981

Cancer Immunol Immunother

View full text Add to dashboard Cite

An indirect immunofluorescence assay is described which specifically detects antibodies against cervical carcinoma-associated membrane antigens. Cells from the ME-180 cervical carcinoma cell line were used as target cells. Sera had to be absorbed with pooled tonsillar lymphocytes prior to use, to remove nonspecific antibodies. The antibody was detected in 61 of 74 patients (82%) with invasive squamous cell carcinoma of the uterine cervix and in 5 of 65 controls (8%). A group of 49 patients with early or preneoplastic stages of this tumor (microinvasive carcinoma, carcinome-in-situ, and dysplasia) did not differ from the control group in the incidence of the antibody (5 of 49 patients, 10%). It is concluded that the occurrence of this antibody is specific for cervical carcinoma (P < 0.001). However, the assay cannot be used as a diagnostic marker for preneoplastic stages of this tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tumor-specific antibodies in sera from patients with squamous cell carcinoma of the uterine cervix

Linde¹,

Streefkerk²,

Velde³

et al. 1981

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Diminution or even loss of lymphocyte function is a frequent though not invariable feature associated with the advanced development of cancer in man [6,16] and experimental animals [12,28]. In the present study, the C3H mammary tumour caused a dramatic reduction in lymphocyte transformation responses of cultured spleen cells from mice bearing the syngeneic tumour produced either by intravenous transplantation, or by metastatic spread from a primary subcutaneous implant that was itself subsequently ablated by direct irradiation.…”

Section: Discussionmentioning

confidence: 54%

Antimetastatic effect of cimetidine on mice bearing a C3H mouse mammary adenocarcinoma: survival and lymphocyte function studies

et al. 1984

View full text Add to dashboard Cite

It has been reported that treatment with cimetidine, a histamine H2-receptor antagonist, increased survival and decreased the number of lung metastases in mice bearing the Lewis Lung carcinoma [29]. It was suggested that this effect was due to the ability of cimetidine to block histamine activation of suppressor lymphocytes and hence allow host defence mechanisms to inhibit tumour growth. In the present studies, C3H/He mice were implanted with a C3H mouse mammary adenocarcinoma on Day 0. This tumour metastasizes to the lungs in 30-50 days. Primary tumours were ablated with X-rays when they had grown to about 0.2 g and animals were given drinking water with or without cimetidine (10 mg ml-1) until the end of the experiment. Cimetidine reduced the number of mice dying from metastatic disease from 7/15 (controls) to 3/13. Cimetidine treatment also prolonged survival of mice that did succumb to metastatic disease by about 12 days. The response of spleen lymphocytes to the mitogens phytohaemagglutinin and lipopolysaccharide was assessed in vitro by uptake of 3H-thymidine 0, 16, 45 and 58 days after tumour implantation. Lymphocyte responsiveness was depressed by tumour burden. The influence of cimetidine treatment was equivocal being dependent upon time after tumour implantation and dose of mitogen. In this mouse-tumour system, the mechanism of the antimetastic effect of cimetidine is different from that previously suggested [29].

show abstract

“…This divergence may be related to the in vivo role of cellular-and antibody-mediated immune reactions to tumour antigens (Cochran, 1978;DiSaia et al, 1972;Ioachim, 1976;Moore, 1978). About twothirds of the patients with preinvasive stages of the tumour were positive in the lymphocyte stimulation test.…”

Section: Discussionmentioning

confidence: 99%

“…Immunosurveillance may be one of the mechanisms which determine the progressive potential of preinvasive lesions (Cochran, 1978;DiSaia et al, 1972;loachim, 1976;Moore, 1978). This prompted us to investigate immune reactivity to antigens of cervical carcinoma cells in patients with invasive and preinvasive stages of cervical carcinoma.…”

mentioning

confidence: 99%

Divergence between the occurrence of antibody and cellular immune reactivity to cervical carcinoma cell lines in preinvasive and macroinvasive stages of cervical carcinoma

Linde¹,

Streefkerk²,

Schuurman³

et al. 1983

Br J Cancer

View full text Add to dashboard Cite

A lymphocyte stimulation assay is described which detects immune reactivity to antigens derived from the CaSki cervical carcinoma cell line. Taking a stimulation index of greater than 4.1 as positive, the peripheral blood lymphocytes of 14/20 patients (70%) with untreated dysplasia or carcinoma-in-situ, 8/19 patients (42%) with untreated macroinvasive squamous cell carcinoma of the uterine cervix and 8/38 controls (21%) showed positive reactions. Statistical analysis revealed a significant difference between the group of patients with dysplasia or carcinoma-in-situ and the controls. The sera of patients and controls were simultaneously tested for the presence of tumour-directed antibody. There was no correlation between the occurrence of cellular immune reactivity and of serum antibody, both directed to cervical carcinoma antigens. Cellular immune reactivity tended to occur more frequently in patients with preinvasive stages of cervical carcinoma, and serum antibody in patients with macroinvasive carcinoma.

show abstract

In vitro testing of the immune response

Cited by 10 publications

References 139 publications

Tumor-specific antibodies in sera from patients with squamous cell carcinoma of the uterine cervix

Tumor-specific antibodies in sera from patients with squamous cell carcinoma of the uterine cervix

Antimetastatic effect of cimetidine on mice bearing a C3H mouse mammary adenocarcinoma: survival and lymphocyte function studies

Divergence between the occurrence of antibody and cellular immune reactivity to cervical carcinoma cell lines in preinvasive and macroinvasive stages of cervical carcinoma

Contact Info

Product

Resources

About